Cargando…

Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide

BACKGROUND: Androgen receptor (AR) signaling inhibitors represent the standard treatment in metastatic castration resistance prostate cancer (mCRPC) patients. However, some patients display a primary resistance, and several studies investigated the role of the AR as a predictive biomarker of respons...

Descripción completa

Detalles Bibliográficos
Autores principales:	Del Re, M., Conteduca, V., Crucitta, S., Gurioli, G., Casadei, C., Restante, G., Schepisi, G., Lolli, C., Cucchiara, F., Danesi, R., De Giorgi, U.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134038/ https://www.ncbi.nlm.nih.gov/pubmed/33500577 http://dx.doi.org/10.1038/s41391-020-00309-w

Ejemplares similares

Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide
por: Conteduca, Vincenza, et al.
Publicado: (2022)

Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide
por: Gurioli, Giorgia, et al.
Publicado: (2020)

Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone
por: Lolli, Cristian, et al.
Publicado: (2016)

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer
por: Salvi, Samanta, et al.
Publicado: (2016)

Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer
por: Conteduca, V., et al.
Publicado: (2017)

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
por: Conteduca, V., et al.
Publicado: (2017)

Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials
por: Moreira, Raphael B., et al.
Publicado: (2017)

Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide
por: Hong, Zhe, et al.
Publicado: (2021)

Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel—an Indirect Comparison
por: Tan, Pui S, et al.
Publicado: (2014)

Plasma Androgen Receptor in Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC
por: White, Ralph E., et al.
Publicado: (2023)

The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment
por: Brighi, Nicole, et al.
Publicado: (2019)

Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer
por: Cursano, M. C., et al.
Publicado: (2022)

Upregulation of PSMA Expression by Enzalutamide in Patients with Advanced mCRPC
por: Rosar, Florian, et al.
Publicado: (2022)

Observational study on time on treatment with abiraterone and enzalutamide
por: Fallara, Giuseppe, et al.
Publicado: (2020)

Plasma androgen receptor and serum chromogranin A in advanced prostate cancer
por: Conteduca, Vincenza, et al.
Publicado: (2018)

Abiraterone In Vitro Is Superior to Enzalutamide in Response to Ionizing Radiation
por: Wright, Timothy C., et al.
Publicado: (2021)

Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?
por: Chen, Ming-kun, et al.
Publicado: (2022)

Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review
por: Cattrini, Carlo, et al.
Publicado: (2022)

Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone
por: Massard, C., et al.
Publicado: (2017)

Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review
por: You, Xiangyun, et al.
Publicado: (2023)

Cardiovascular toxicities associated with abiraterone compared to enzalutamide–A pharmacovigilance study
por: Cone, Eugene B., et al.
Publicado: (2021)

Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
por: Talwar, Harkirat Singh
Publicado: (2021)

Outcomes Following Abiraterone versus Enzalutamide for Prostate Cancer: A Scoping Review
por: Shah, Yash B., et al.
Publicado: (2022)

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment
por: Attard, Gerhardt, et al.
Publicado: (2018)

Implications of KRAS mutations in acquired resistance to treatment in NSCLC
por: Del Re, Marzia, et al.
Publicado: (2017)

A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide
por: Petrylak, D.P., et al.
Publicado: (2021)

Enzalutamide: the emperor of all anti-androgens
por: Antonarakis, Emmanuel S.
Publicado: (2013)

Response to flutamide, as second-line therapy after bicalutamide, predicts efficacy of abiraterone, not that of enzalutamide
por: Nakai, Yasushi, et al.
Publicado: (2018)

Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients
por: Kulkarni, A.A., et al.
Publicado: (2021)

Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
por: Rana, Dikshyanta, et al.
Publicado: (2021)

Comparative Effectiveness of Abiraterone and Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer in Taiwan
por: Li, Pei-Yu, et al.
Publicado: (2022)

Idarubicin combats abiraterone and enzalutamide resistance in prostate cells via targeting XPA protein
por: Zhang, Ying, et al.
Publicado: (2022)

Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors
por: Schepisi, Giuseppe, et al.
Publicado: (2020)

Combining liquid biopsy and functional imaging analysis in metastatic castration‐resistant prostate cancer helps predict treatment outcome
por: Conteduca, Vincenza, et al.
Publicado: (2021)

Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment
por: Arrigoni, Elena, et al.
Publicado: (2018)

Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide
por: Belic, Jelena, et al.
Publicado: (2018)

Physician Dispensing Among Urology Practices and the Use of Abiraterone or Enzalutamide for Men With Advanced Prostate Cancer
por: Lai, Lillian Y, et al.
Publicado: (2022)

Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer
por: Demirci, Ayşe, et al.
Publicado: (2021)

Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment
por: Mei, Zejie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_eicc3242c5r1lpcbgu3laru82m